Protecting Pharmaceutical Profits: The Cost Is Human Lives
Read More:
Anna Eshoo,
Dr. Anthony So,
Breast Cancer,
Crohn's Disease,
Herceptin,
Kay Hagan,
Biologics,
Amsa,
Politics News
The public option has received the lion's share of attention in the health care debate, but there's an equally important issue relating to generic drugs that could mean lifesaving drugs remain too expensive for all but the wealthy.









Jane Hamsher | Posted 10.27.2009 | Politics